Ipsen Pharma S.a.s v Allergan, Inc

Link copied
Case Copied 39 min read

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Ipsen Pharma S.A.S v Allergan, Inc [2012] APO 21

Patent Application:                2005200251

Title:Method for treating pain associated with a muscle disorder

Patent Applicant:                   Allergan, Inc

Opponent:  Ipsen Pharma S.A.S.

Delegate:  Dr Leslie F. McCaffery

Decision Date:  7 February 2012

Hearing Date:  21 September 2011, in Canberra

Catchwords:  PATENTS – opposition to grant – requests for further evidence by both the Applicant and the Opponent – an adequate explanation of the delay not provided by the Opponent – nature and significance of the evidence justifies further evidence – fair basis and priority date of the claims – claimed invention fairly based on earlier applications – novelty – construing citations – features disclosed by the prior art – claims lack novelty – inventive step – claims lack inventive step – section 40 ­– claims are clear and fully described – best method has been provided– utility – no evidence to show that claimed matter would not produce the desired result – new manner of manufacture – on the face of the specification the invention was not known

Representation:  Patent applicant:  Dr Gavin Recchia and Dr Nigel Lokan of Davies Collison Cave (Sydney)

Opponent:Mr Ian Horak of Counsel, instructed by Ms Amanda Jones of Watermark (Melbourne)

IP AUSTRALIA

AUSTRALIAN PATENT OFFICE

Patent Application:                2005200251

Title:Method for treating pain associated with a muscle disorder

Patent Applicant:                   Allergan, Inc

Date of Decision:                   7 February 2012

DECISION

The opposition succeeds.  The subject matter of Claims 1 to 7 lacks novelty and inventive step.  Allergan is allowed 2 months from the date of this decision to file amendments to address the deficiencies.  Costs according to Schedule 8 are awarded against Allergan.

REASONS FOR DECISION

Background

1.   Patent application 2005200251 was filed on 21 January 2005 by Allergan, Inc (hereinafter the Applicant).  This application is a divisional of application 29231/02 (the parent), which is a divisional of 16361/00 (the grandparent), which is a divisional of 70105/98 (712502, the great grandparent), which in turn is a divisional of 15162/95 (688452 the great-great grandparent).  The application is also related to numerous other applications which derive from 15162/95, but these are of little relevance to the present matter and I will not discuss these in detail in this decision.

2.   A notice of opposition was served on the Applicant by Societe de Conseils de Recherches et D’Applications Scientifiques (S.C.R.A.S., hereinafter the Opponent) on 18 April 2007.  The Opponent later requested that its name be changed to Ipsen Pharma S.A.S.  on 12 March 2009, and this change was recorded on 15 April 2009.

3.   A Statement of Grounds and Particulars was on served on 17 July 2007. 

4.   Evidence in support was completed on 24 July 2009 and comprises the following declarations:

  • Statutory declaration of Amanda Lee Jones dated 7 May 2009 and Exhibits ALJ-1 to 6 (Jones 1).
  • Statutory declaration of Mithu Abhik Palit dated 25 May 2009 and Exhibits MAP-1 to 10 (Palit 1).
  • Statutory declaration of Amanda Lee Jones dated 21 July 2009 and…
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Ipsen Pharma S.a.s v Allergan, Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2012] APO 21
Decision Date

CaseChat Overview and Summary

Ipsen Pharma S.A.S opposed the grant of a patent to Allergan, Inc, in respect of a method for treating pain associated with a muscle disorder. The opposition was heard by Dr Leslie F. McCaffery on 21 September 2011 in Canberra. The decision was handed down on 7 February 2012. The opposition was successful on the grounds of novelty and lack of inventive step. The decision was that the claims in the patent application lacked novelty and inventive step. The Commissioner of Patents allowed Allergan 2 months from the date of the decision to file amendments to address the deficiencies. Costs were awarded against Allergan in accordance with Schedule 8.

The Commissioner found that the claims in the patent application lacked novelty because they had been disclosed in prior art. The Commissioner found that the claims were not fairly based on earlier applications, and that the priority date was 28 December 1993. The Commissioner found that the claims were anticipated by prior art disclosures, specifically Konstanzer and Memin.

The Commissioner found that the claims also lacked inventive step. The Commissioner found that it would have been obvious to proceed to the claimed invention in light of the prior art. The Commissioner found that the claims lacked inventive step in view of Konstanzer and Memin.

The Commissioner found that the claims were not lacking in utility, manner of manufacture, clarity or a full description. The Commissioner found that the claims were clear and fully described, and that the best method of performing the invention had been provided. The Commissioner allowed Allergan 2 months from the date of the decision to file amendments to address the deficiencies. Costs were awarded against Allergan in accordance with Schedule 8.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.